ATLAS study: Treat-and-extend with aflibercept reduces AMD treatment burden

SAN FRANCISCO — Treat-and-extend aflibercept therapy for neovascular age-related macular degeneration improved vision and significantly reduced the treatment burden at 2 years, according to a scientific poster presented here at the American Society of Retina Specialists meeting. “A treat-and-extend injection protocol using aflibercept for neovascular age-related macular degeneration allowed more than a third of patients to achieve an injection interval of 12 weeks or longer,” lead author David C. Reed, MD, wrote.